Accuray Incorporated (NASDAQ:ARAY) is expected to report fourth quarter earnings results, after market close, on Thursday 13th August 2020.
Analysts polled by Thomson Reuters anticipate fourth quarter loss of $ 0.02 per share.
Looking ahead, the full year income are expected at $ 0.02 per share on the revenues of $ 379.52 million.
The Company Outlook
Full Year 2020 topline are forecasted in a range of$ 410.00 million ~ $ 420.00 million
Click Here For More Historical Outlooks Of Accuray Incorporated
Previous Quarter Performance
Accuray Incorporated reported income for the third quarter of $ 0.03 per share, from the revenue of $ 99.55 million. The quarterly revenues lowered 3.56 percent compared with the same quarter last year. Street analysts expected Accuray Incorporated to report loss of $ 0.03 per share on revenue of $ 100.16 million for the third quarter. The bottom line results beat street analysts by $ 0.06 or 200.00 percent, at the same time, top line results fell short of analysts by $ 0.61 million or 0.61 percent.
Historical Earnings Performance
wpDataChart with provided ID not found! wpDataTable with provided ID not found!Click Here For More Historical Earnings Of Accuray Incorporated
Stock Performance
According to the previous trading day, closing price of ARAY was $ 2.73, representing a 105.26 % increase from the 52 week low of $ 1.33 and a 41.67 % decrease over the 52 week high of $ 4.68.
The company has a market capital of $ 247.11 million and is part of the Healthcare sector and Medical Appliances & Equipment industry.
[stock_market_widget type=”chart” template=”basic” color=”orange” assets=”ARAY” range=”1y” interval=”1mo” axes=”true” cursor=”true” api=”yf” style=”height: 400px;”]
Conference Call
Accuray Incorporated will be hosting a conference call at 7:00 PM eastern time on 13th August 2020, to discuss its 4Q20 financial results with the investment community. A live webcast with presentations will be available on the Internet by visiting the Company website www.accuray.com
Accuray Incorporated designs, develops, and sells radiosurgery and radiation therapy systems for the treatment of tumors in the body. The company offers the CyberKnife System, a robotic stereotactic radiosurgery and stereotactic body radiation therapy system used for the treatment of various types of cancer and tumors in the body. Its CyberKnife System automatically tracks, detects, and corrects for tumor and patient movement in real-time during the procedure, as well as enables the delivery of precise, high dose radiation while patients breathe normally.
